Molecular epidemiology of human cancer: Biomarkers of genotoxic exposure and susceptibility

Journal of Environmental Pathology, Toxicology and Oncology

Volumn 20, Issue 4, 2001, Pages 245-261

  Grant, Stephen G ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Carcinogenesis; DNA repair; Genetic toxicology; GPA; HPRT; Mutagen sensitivity; Mutagenesis

Indexed keywords

BIOLOGICAL MARKER; CARCINOGEN; DNA; GLYCOPHORIN A; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MUTAGENIC AGENT;

CANCER; CANCER GROWTH; CARCINOGENESIS; CONFERENCE PAPER; CONTROLLED STUDY; DNA REPAIR; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HUMAN; MOLECULAR BIOLOGY; MONITORING; MUTAGENESIS; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0035684556     PISSN: 07318898     EISSN: None     Source Type: Journal    
DOI: 10.1615/jenvironpatholtoxicoloncol.v20.i4.10     Document Type: Conference Paper

References (135)

1. Biological markers in epidemiologic research
2. A conceptual framework for the validation and use of biologic markers
3. Epidemiological studies using biological markers: Issues for epidemiologists
4. Carcinogenesis
5. The clonal evolution of tumor cell populations
6. The molecular genetics of cancer
7. Recessive mechanisms of malignancy
8. Genetic alterations during colorectal-tumor development
9. Carcinogenic potency database
10. Genotoxicity database
11. Potential of machine-vision light microscopy in toxicologic pathology
12. Genetic toxicology
13. Uses and future applications of flow cytometry in immunotoxicity testing
14. Liquid chromatography-mass spectrometry in forensic toxicology
15. High-throughput screening. Advances in robotics and miniaturization continue to accelerate drug lead identification
16. New assay technologies for high-throughput screening
17. Extraction of pharmacophore information from high-throughput screens
18. High-throughput and ultra-high-throughput screening: Solution- and cell-based approaches
19. Computational predictive programs (expert systems) in toxicology
20. Quantitative structure-based modeling applied to characterization and prediction of chemical toxicity
21. Development, characterization and application of predictive-toxicology models
22. In silico toxicology
23. The role of epidemiology in elucidating the importance of environmental factors in human cancer
24. An ISFET-algal (Chlamydomonas) hybrid provides a system for eco-toxicological tests
25. In vitro analysis of xenoestrogens by enzyme linked receptor assays (ELRA)
26. Biological monitoring
27. An introduction to metabolic and kinetic aspects of toxicological studies
28. Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response
29. Metabolism of chemical carcinogens
30. The use of computers in the safety evaluation of drugs and other chemicals
31. META. 1. A program for the evaluation of metabolic transformation of chemicals
32. Molecular characterization of glycophorin A transcripts in human erythroid cells using RT-PCR, allele-specific restriction, and sequencing
33. Characterization of a polymorphism in NAD(P)H:Quinone oxidoreductase (NQO1, DT-diaphorase)
34. 32p]-labeling test for DNA damage
35. Immunological methods for detection of carcinogen-DNA damage in humans
36. Carcinogen macromolecular adducts and their measurement
37. New molecular endpoints and methods for routine toxicity testing
38. Cancer risk in humans predicted by increased levels of chromosomal aberrations in lymphocytes: Nordic study group on the health risk of chromosome damage
39. Chromosomal aberrations in lymphocytes predict human cancer: A report from the European study group on cytogenetic biomarkers and health
40. Chromosomal aberrations in lymphocytes predict human cancer independently of exposure to carcinogens
41. Mammalian cell genetics. II. Chemical induction of specific locus mutations in Chinese hamster cells in vitro
42. Enumeration of 6-thioguanine-resistant peripheral blood lymphocytes in man as a potential test for somatic cell mutations arising in vivo
43. Measurement of in vivo mutations in human lymphocytes
44. Allele loss at the human GPA locus: A model for recessive oncogenesis with potential clinical application
45. In vivo somatic mutation and segregation at the human glycophorin A (GPA) locus: Phenotypic variation encompassing both gene-specific and chromosomal mechanisms
46. Use of hematopoietic cells and markers for the detection and quantitation of human in vivo somatic mutation
47. Evidence for increased somatic cell mutations at the glycophorin A locus in atomic bomb survivors
48. Analysis of somatic cell mutations at the glycophorin A locus in atomic bomb survivors: A comparative study of assay methods
49. Increased somatic cell mutant frequency in atomic bomb survivors
50. Elevated frequency of glycophorin A mutations in erythrocytes from Chernobyl accident victims
51. Radiobiological evaluation of immigrants from the vicinity of Chernobyl
52. Novel biodosimetry methods applied to victims of the Goiânia accident
53. Molecular analysis of in vivo HPRT mutations in human T lymphocytes. V. Effects of total body irradiation secondary to radioimmunoglobulin therapy (RIT)
54. Bone marrow somatic mutation after genotoxic cancer therapy
55. Possible association between mutant frequency in peripheral lymphocytes and domestic radon concentrations
56. Mutant frequency of radiotherapy technicians appears to be associated with recent dose of ionizing radiation
57. Biodosimetry for a radiation worker using multiple assays
58. Factors affecting HPRT mutant frequency in T-lymphocytes of smokers and nonsmokers
59. Elevated frequencies of HPRT mutantlymphocytes in cigarette-smoking mothers and their newborns
60. Genotoxic effects of occupational exposure in the peripheral blood lymphocytes of pesticide preparing workers in Hungary
61. Use of the glycophorin A human mutation assay to study workers exposed to styrene
62. HPRT and glycophorin A mutations in foundry workers: Relationship to PAH exposure and to PAH-DNA adducts
63. Effects of lymphocyte subpopulations on the clonal assay of HPRT mutants: Occupational exposure to cytostatic drugs
64. Benzene induces gene-duplicating but not gene-inactivating mutations at the glycophorin A locus in exposed humans
65. Somatic cell gene mutations in humans: Biomarkers for genotoxicity
66. Somatic-cell mutations as a possible predictor of cancer risk
67. Detection of 6-thioguanine resistance in human peripheral blood lymphocytes (PBL) of industrial workers and lung cancer patients
68. Factors influencing mutation at the HPRT locus in T-lymphocytes: Studies in normal women and women with benign and malignant breast masses
69. Evidence for increased somatic cell mutations in patients with hepatocellular carcinoma
70. Flow cytometric measurements of somatic cell mutations in Thorotrast patients
71. Somatic mutations at T-cell antigen receptor and glycophorin A loci in pediatric leukemia patients following chemotherapy: Comparison with HPRT locus mutation
72. Do mutations at the glycophorin A locus in patients treated for childhood Hodgkin's disease predict secondary leukaemia?
73. Glycophorin A mutations and risk of secondary leukaemia in patients treated for childhood acute lymphoblastic leukaemia
74. The effect of chemotherapy on the in vivo frequency of glycophorin A "null" variant erythrocytes
75. Multiple biological markers in germ cell tumor patients treated with platinum-based chemotherapy
76. Drug-resistant lymphocytes in man as indicators of somatic cell mutation
77. The emergence of 6-thioguanine-resistant lymphocytes in pediatric cancer patients
78. Increased mutation frequency following treatment with cancer chemotherapy
79. In vivo mutant frequency rises among breast cancer patients after exposure to high doses of γ-radiation
80. Genotoxic effects of radiotherapy and chemotherapy on the circulating lymphocytes of breast cancer patients. III. Measurement of mutant frequency to 6-thioguanine resistance
81. Comparison of HPRT variant frequencies and chromosome aberration frequencies in lymphocytes from radiotherapy and chemotherapy patients: A prospective study
82. Factors influencing mutation at the HPRT locus in T-lymphocytes: Women treated for breast cancer
83. In vivo somatic mutation in the lymphocytes of Hodgkin's disease patients
84. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo
85. Bloom's syndrome: Evidence for an increased mutation frequency in vivo
86. Spontaneous 6-thioguanine-resistant lymphocytes in Fanconi anemia patients and their heterozygous parents
87. Frequencies of HPRT-lymphocytes and glycophorin A variants erythrocytes in Fanconi anemia patients, their parents and control donors
88. Detection of somatic mutations in man: Evaluation of the microtitre cloning assay for T-lymphocytes
89. Cloning efficiency and spontaneous mutant frequency in circulating T-lymphocytes in ataxia-telangiectasia patients
90. Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia
91. Evidence for elevated in vivo mutations and somatic recombination in Bloom's syndrome
92. Frequency of variant erythrocytes at the glycophorin-A locus in two Bloom's syndrome patients
93. Diagnosis of ataxia telangiectasia with the glycophorin A somatic mutation assay
94. Detection of somatic mutants in man: HPRT mutations in lymphocytes and hemoglobin mutations in erythrocytes
95. Elevated HPRT mutant frequency in circulating T-lymphocytes of xeroderma pigmentosum patients
96. The glycophorin A assay for somatic cell mutations in humans
97. Increased frequency of 6-thioguanine-resistant peripheral blood lymphocytes in Werner syndrome patients
98. Genetic instability and hematologic disease risk in Werner syndrome patients and heterozygotes
99. Genetic instability in the human population: A working hypothesis
100. Prenatal detection of the Fanconi's anemia gene by cytogenetic methods
101. Ataxia telangiectasia: An inherited human disorder involving hypersensitivity to ionizing radiation and related DNA-damaging chemicals
102. Specific cellular defects in patients with Fanconi anemia
103. Bleomycin-induced chromosome damage in lymphocytes of medullary thyroid carcinoma patients and their family members
104. Differential mutagen susceptibility in cultured lymphocytes of normal individuals and cancer patients
105. Sensitivity to genotoxic effects of bleomycin in humans: Possible relationship to environmental carcinogenesis
106. Mutagen sensitivity: A biological marker of cancer susceptibility
107. Chromosome sensitivity to bleomycin-induced mutagenesis: An independent risk factor for upper aerodigestive tract cancer
108. Mutagen sensitivity in upper aerodigestive tract cancer: A case-control analysis
109. Genetic susceptibility to head and neck squamous cell carcinoma
110. A case-control study of nonrandom distribution of bleomycin-induced chromatid breaks in lymphocytes of lung cancer cases
111. A parallel study of in vitro sensitivity to benzo[a]pyrene diol epoxide and bleomycin in lung carcinoma cases and controls
112. Differential sensitivity among three human subpopulations in response to 4-nitroquinoline-1-oxide and to bleomycin
113. Cytogenetic studies in the genotoxicity of 4-nitroquinoline-1-oxide on human cells in vitro
114. In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer
115. Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer
116. Mutation, segregation, and childhood cancer
117. A survey of the actualities and potentialities of exfoliate cytology in cancer diagnosis
118. Nucleic acid-based methods for the detection of cancer
119. Free DNA in the serum of cancer patients and the effect of therapy
120. Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease
121. The origin and mechanism of circulating DNA
122. DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells
123. Soluble normal and mutated DNA sequences from single-copy genes in human blood
124. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer
125. Microsatellite alterations in plasma DNA of small cell lung cancer patients
126. Microsatellite alterations in serum DNA of head and neck cancer patients
127. Viral carcinogenesis: Revelation of molecular mechanisms and etiology of human disease
128. Heredity and environment in the origin of cancer
129. Mutator phenotypes in human colorectal carcinoma cell lines
130. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
131. Hormonal carcinogenesis
132. Surrogate endpoint biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials
133. Prostatic intraepithelial neoplasia and other changes during promotion and progression